Source: Annual Congress 2012 - Clinical issues in malignant pleural effusions
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
B. Komurcuoglu, K.A. Cirak, N. Yucel, G. Polat, O. Usluer (Izmir, Turkey). Prognostic factors and survival in malignant pleural mesothelioma at a large tertiary referral center in Turkey. Eur Respir J 2012; 40: Suppl. 56, 1255

Member's Comments

No comment yet.

Related content which might interest you: Determinants of survival in patients with malignant pleural mesothelioma (MPM) managed at a single institution in Liguria, Italy Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018 Factors effecting malignant pleural mesothelioma incidence in rural part of Eskisehir, Turkey Source: Eur Respir J 2001; 18: Suppl. 33, 534s Year: 2001 Prognostic value of treatment outcomes patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 The analysis of clinicopathological characteristics and prognosis of malignant pleural mesothelioma Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases Year: 2013 Prognostic factors in diffuse malignant pleural mesothelioma Source: Eur Respir J 2003; 22: Suppl. 45, 62s Year: 2003 Prognostic factors in diffuse malignant pleural mesothelioma Source: Eur Respir J 2007; 30: Suppl. 51, 755s Year: 2007 A 10-year experience of pleurodesis for malignant pleural effusion in a district general hospital Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Prognostic characteristics of malignant pleural mesothelioma Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Is comorbidity a good prognostic factor for malignant pleural mesothelioma? Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008 Therapeutic outcome and prognostic factors in patients with pleural mesothelioma Source: Eur Respir J 2005; 26: Suppl. 49, 73s Year: 2005 Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018 Salvage treatment in patients with recurrent or resistant malignant pleura mesothelioma. A retrospective study from tertiary oncology department Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 Clinical and morphological prognostic factors in patients with malignant pleura mesothelioma (MPM) Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Prognostic significance of pretreatment clinical and laboratory characteristics in patients with diffuse malignant pleural mesothelioma Source: Eur Respir J 2006; 28: Suppl. 50, 784s Year: 2006 Malignant pleural mesothelioma:a 16-year, single centre experience Source: International Congress 2017 – Pleural and mediastinal malignancies Year: 2017 Clinical and biological prognostic factors in malignant pleural effusion (MPE) secondary to breast cancer Source: Annual Congress 2005 - What's new in the pleura Year: 2005 Pre-therapeutic staging and prognostic factors in malignant pleural mesothelioma patients Source: Annual Congress 2009 - Malignant pleural mesothelioma guidelines Year: 2009 Malignant pleural mesothelioma clinical aspects and survival in 93 cases Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Malignant pleural mesothelioma (MPM): clinical presentation, complications and survival Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002 The referral to diagnosis time for patients with malignant effusions presenting to a respiratory pleural clinic Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010